Home Biosimilar Antibodies Immunology & Inflammation CD markers Anti-TSPAN26 / CD37 (AGS67E)
For research use only. Not for use in humans.

Anti-TSPAN26 / CD37 (AGS67E)

Synonyms: CD37,Tspan-26

Anti-TSPAN26 / CD37 (AGS67E) is a fully human monoclonal antibody that targets CD37. It is used for the potential treatment of B/T-cell malignancies. MW :143.44 KD.

Anti-TSPAN26 / CD37 (AGS67E)

Quality Control

Batch: A310501 Purity: 99% Protein concentration: 5.49mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-TSPAN26 / CD37 (AGS67E) is a fully human monoclonal antibody that targets CD37. It is used for the potential treatment of B/T-cell malignancies. MW :143.44 KD.
References

Product Details

Isotype Human IgG2SA
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02175433 COMPLETED Drug: AGS67E Relapsed Lymphoid Malignancy; Refractory Lymphoid Malignancy Astellas Pharma Global Development, Inc. 2014-10-14 PHASE1
NCT02610062 TERMINATED Drug: AGS67E Acute Myeloid Leukemia Astellas Pharma Global Development, Inc. 2016-03-29 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-11-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.